21:41 , Aug 10, 2018 |  BioCentury  |  Finance

Wnt to market

With no traditional life science VCs in its syndicate and little publicly disclosed about its science, Samumed LLC was able to raise a $438 million round at a premoney valuation of $12 billion, bringing its...
18:48 , Apr 20, 2018 |  BC Week In Review  |  Clinical News

Opdivo gets Priority Review for third-line SCLC

Bristol-Myers Squibb Co. (NYSE:BMY) said FDA accepted and granted Priority Review to an sBLA for Opdivo nivolumab to treat small cell lung cancer in patients whose disease has progressed after two or more prior therapies....
22:51 , Apr 18, 2018 |  BC Extra  |  Company News

Opdivo gets Priority Review for third-line SCLC

Bristol-Myers Squibb Co. (NYSE:BMY) said FDA accepted and granted Priority Review to an sBLA for Opdivo nivolumab to treat small cell lung cancer in patients whose disease has progressed after two or more prior therapies....
23:09 , Apr 6, 2018 |  BioCentury  |  Finance

Fundamentally driven

Continued struggles by the mega-cap bellwethers and the resurgence of volatility in global equity markets were the major themes of 1Q18, whipsawing biotech stocks throughout the quarter but leaving index values little changed on the...
22:51 , Apr 6, 2018 |  BioCentury  |  Finance

Picking season

  Macroeconomic risks, surging volatility and a tail-off in the M&A market since January have done little to change the buyside’s strategy of overweighting small- and mid-cap biotechs. In fact, the 12 investors who spoke...
19:12 , Mar 30, 2018 |  BioCentury  |  Finance

Rova-T roadblock

A setback for lung cancer candidate Rova-T rovalpituzumab tesirine from AbbVie Inc. (NYSE:ABBV) has buysiders skeptical of the pharma’s broader business development strategy. On March 22, AbbVie said it will not seek FDA accelerated approval...
16:57 , Mar 23, 2018 |  BC Week In Review  |  Clinical News

AbbVie not seeking accelerated approval of SCLC candidate

AbbVie Inc. (NYSE:ABBV) said it will not seek accelerated approval from FDA for Rova-T rovalpituzumab tesirine (SC16LD6.5) as third-line treatment of relapsed or refractory small cell lung cancer (SCLC). The company based its decision on...
22:29 , Mar 22, 2018 |  BC Extra  |  Clinical News

AbbVie not seeking accelerated approval of SCLC candidate

AbbVie Inc. (NYSE:ABBV) said Thursday that it will not seek accelerated approval from FDA for Rova-T rovalpituzumab tesirine as third-line treatment of relapsed or refractory small cell lung cancer. The company based its decision on...
22:06 , May 11, 2017 |  BC Innovations  |  Tools & Techniques

Stemming the tide

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...
01:05 , Apr 21, 2017 |  BC Innovations  |  Product R&D

Making marks at AACR

Biomarkers that could stratify patients, point to treatment combinations or predict toxicity were a major part of the conversation at this year’s AACR conference, where they emerged as potential difference makers for a range of...